#5-92E. Unraveling Sjögren’s Pathogenesis: Th1/Treg Imbalance and JAK Inhibition (SciTranslMed, 2024)

Sjögren’s Disease lacks targeted immunomodulatory therapies due to an incomplete understanding of its underlying immune drivers. This study demonstrates that Ca²⁺ signaling-deficient, dysfunctional regulatory T cells allow IFN-γ–producing Th1 cells to drive glandular pathology, which can be rescued by the JAK1/2 inhibitor baricitinib—though findings rely heavily on a murine genetic model that exhibits multi-organ inflammation beyond classic exocrine involvement. These findings highlight the pathogenic role of Th1/IFN-γ signaling in exocrine tissue damage, offering a novel rationale for evaluating JAK inhibitors in clinical Sjögren’s Disease management.

Citation: Y.-H. Wang, W. Li, M. McDermott, et al., S. Feske. IFN-γ-producing Th1 cells and dysfunctional regulatory T cells contribute to the pathogenesis of Sjögren’s Disease. Science Translational Medicine. 2024.

URL: https://doi.org/10.1126/scitranslmed.ado4856

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.